| |
 |
 |
| Therapy in hormone resistant prostate cancer |
| |
Redefining response criteria for clinical trials
M. Hussain
|
[
Modem ]
|
Modem
|
| |
|
| |
Chemotherapy, when and why?
R. De Wit
|
[
Modem ]
|
Modem
|
| |
|
| |
Aberaterone, methylation inhibitors and other novel targets in development
J. De Bono
|
[
Modem ]
|
Modem
|
| |
|
| |
Novel therapeutics in clinical trials
M. Eisenberger
|
[
Modem ]
|
Modem
|
| |
